These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11775935)

  • 21. Fosamprenavir: a new PI option. Interview by Craig Sterritt.
    Nadler J
    IAPAC Mon; 2004 Feb; 10(2):50-2. PubMed ID: 15106520
    [No Abstract]   [Full Text] [Related]  

  • 22. Controversies in current treatment guidelines.
    Gazzard BG
    J HIV Ther; 2008 Mar; 13(1):1-3. PubMed ID: 18953266
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-HIV drug update.
    Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nevirapine and delavirdine plus protease inhibitors.
    GMHC Treat Issues; 1996 Apr; 10(4):8. PubMed ID: 11363709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral rounds. Putting resistance to work.
    Daar ES; Elion R
    AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
    [No Abstract]   [Full Text] [Related]  

  • 26. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 27. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 28. Rescue regimens: the value of PI boosting.
    Segal-Maurer S; Schütz M
    Posit Aware; 2001; 12(6):35-7. PubMed ID: 11785478
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
    Katzenstein DA
    AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
    Gathe JC; Elion R
    AIDS Clin Care; 2008 Jun; 20(6):51-2. PubMed ID: 18661634
    [No Abstract]   [Full Text] [Related]  

  • 31. ICAAC clinical trials review available.
    AIDS Treat News; 2002 Oct; (384):5. PubMed ID: 12434763
    [No Abstract]   [Full Text] [Related]  

  • 32. [Seropositivity. Antiretrovirus treatments].
    Tubiana R
    Soins; 1998; (622):19-23. PubMed ID: 9574066
    [No Abstract]   [Full Text] [Related]  

  • 33. Drugs for HIV Infection.
    Treat Guidel Med Lett; 2004 Jan; 2(17):1-8. PubMed ID: 15529108
    [No Abstract]   [Full Text] [Related]  

  • 34. WHO issues treatment guidelines for HIV/AIDS.
    AIDS Policy Law; 2002 May; 17(9):1. PubMed ID: 12030233
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of once-daily antiretroviral therapy.
    Boyle BA
    AIDS Read; 2002 Mar; 12(3):90-2, 95-6, 109. PubMed ID: 11966243
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opportunistic pricing: a new scourge, a new call for action.
    Proj Inf Perspect; 1998 Dec; (26):1-5. PubMed ID: 11366486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No nukes please.
    TreatmentUpdate; 2002 Nov; 14(8):6. PubMed ID: 12501825
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.